Study of ORX142 in Healthy Adults Ages 18 to 80
Part of Brain & nervous system, Mental health clinical trials.
This study tests an experimental drug called ORX142 in healthy volunteers to see how it is processed by the body. It helps doctors understand the drug's safety before testing in patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are generally healthy, with no major medical conditions like heart, lung, kidney, or neurological disease.
- You do not have a history of seizures or any condition that increases your risk for seizures.
- You do not have a diagnosed sleep disorder (like sleep apnea or severe insomnia).
- Your age is either 18 to 55 (for most study groups) or 60 to 80 (for a specific older group).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 1 trial is testing an experimental drug called ORX489 in healthy adults aged 18 to 60. The goal is to see if it is safe and how the body processes it, which helps decide if it can be tried in people with certain conditions.
This trial tests an experimental drug called ORX750 for people with narcolepsy or idiopathic hypersomnia. You would need to stop your current sleepiness medicines to see if ORX750 helps reduce daytime sleepiness.
This trial is for people who have already completed the main CRYSTAL-1 study of ORX750. It tests the long-term safety and effects of the drug, so you can continue treatment if it was helping you.
This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.
This trial tests a new medicine called ALKS 2680 for people with Idiopathic Hypersomnia (a condition that causes extreme sleepiness without a clear cause). The goal is to see if it is safe and effective at helping you stay awake during the day.
This study tests a new drug called E2086 to see if it can help reduce daytime sleepiness and sudden muscle weakness in adults with narcolepsy. It involves two groups: people with cataplexy (type 1) and those without (type 2).
Hear when a new Excessive Daytime Sleepiness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.